

PHARMANUTRA: GOLDEN POWER NOTIFICATION FILED IN CONNECTION WITH THE ACQUISITION OF 100% OF AKERN S.R.L.

Pisa, 17 June 2022 - [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specializing in iron and mineral-based nutritional supplements and medical devices for muscles and joints, informs that it has notified today, pursuant to and for the purposes of Article 2 of Decree Law No. 21/2012, converted into Law No. 56/2012, to the Presidency of the Council of Ministers (so-called "Golden Power" notification) the transaction for the acquisition of 100% of the corporate capital of Akern S.r.l. ("Akern") - a company active in the research, development, production and sale of medical instrumentation and software for the monitoring of body composition using bio-impedance techniques - announced to the market on June 15, 2022 (the "Transaction").

In particular, obtaining the "Golden Power" authorization constitutes one of the conditions to the completion of the Transaction, which provides for the acquisition by Pharmanutra of the stakes held in Akern by Red Lions S.p.A. (owner of a stake equal to 72.96%) and Jacopo Talluri (owner of a stake equal to 13.52%), by July 2022, and by Liside S.r.l. (owner of a stake equal to the remaining 13.52%), by December 2022, for a total consideration of Euro 12 million.

As already communicated last June 15, the parties also provided for the recognition of an earn-out to the sellers of up to a maximum of Euro 3 million upon the achievement of targets linked to Akern's EBITDA and industrial margin, calculated on the basis of the results of fiscal years 2022, 2023 and 2024. In the fiscal year 2021, Akern reported revenues from sales of Euro 4.109.439, a turnover of Euro 4.188.919, an EBITDA of Euro 1.160.441, a net income of Euro 577.276 and a net financial position (cash) at 31st of December 2021 of Euro 846.665.

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra is a company incorporated in 2003 that develops unique nutritional supplements and innovative nutritional devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated through numerous scientific evidences, including 135 publications with more than 7,000 subjects involved. The Group distributes and sells in Italy and abroad. In Italy, sales activity is carried out through a network of over 160 Scientific Sales Representatives serving the medical profession, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 60 countries through 42 partners selected among the best pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL[®], where it owns important patents on Sucrosomal Technology[®]. The Group has developed over the years a precise strategy in the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

PharmaNutra.it

For more information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa
Tel. +39 050 7846500
investorrelation@PharmaNutra.it

Internal Press Office
press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com